Abstract:Background Early diagnosis and typing are crucial for improving the prognosis of patients with renal amyloidosis. Currently, Untargeted proteomics based precise diagnosis and typing of amyloid deposits are crucial for guiding patient management. Although untargeted proteomics achieve ultra-high-throughput by selecting the most abundant eluting cationic peptide precursors in series for tandem MS events, it lacks in sensitivity and reproducibility, which may not be suitable for early-stage renal amyloidosis with minor damages. Here, we aimed to develop parallel reaction monitoring (PRM)-based targeted proteomics to achieve high sensitivity and specificity by determining absolute abundances and codetecting all transitions of highly repeatable peptides of preselected amyloid signature and typing proteins in identifying early-stage renal immunoglobulin-derived amyloidosis. Methods and results In 10 discovery cohort cases, Congo red-stained FFPE slices were micro-dissected and analyzed by data-dependent acquisition-based untargeted proteomics for preselection of typing specific proteins and peptides. Further, a list of proteolytic peptides from amyloidogenic proteins and internal standard proteins were quantified by PRM-based targeted proteomics to validate performance for diagnosis and typing in 26 validation cohort cases. The diagnosis and typing effectiveness of PRM-based targeted proteomics in 10 early-stage renal amyloid cases was assessed via a comparison with untargeted proteomics. A peptide panel of amyloid signature proteins, immunoglobulin light chain and heave chain in PRM-based targeted proteomics showed significantly distinguishing ability and amyloid typing performance in patients. The diagnostic algorithm of targeted proteomics with a low amount of amyloid deposits in early-stage renal immunoglobulin-derived amyloidosis showed better performance than untargeted proteomics in amyloidosis typing. Conclusions This study demonstrates that the utility of these prioritized peptides in PRM-based targeted proteomics ensure high sensitivity and reliability for identifying early-stage renal amyloidosis. Owing to the development and clinical application of this method, rapid acceleration of the early diagnosis, and typing of renal amyloidosis is expected.

Early diagnosis of transthyretin amyloidosis by detection of monomers in plasma microsamples using a protein crystal-based assay

Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients

Detection of ATTR aggregates in plasma of polyneuropathic ATTR-V30M amyloidosis patients

Structure-based probe reveals the presence of large transthyretin aggregates in plasma of ATTR amyloidosis patients

A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH

Enhanced detection of ATTR amyloid using a nanofibril-based assay

An ultra performance liquid chromatography method for transthyretin variants screening and heart failure assisting diagnosis

Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody

Recent Progress in Fluorescent Probes for Transthyretin Sensing

Small molecule amyloid disrupters demonstrate therapeutic efficacy for transthyretin amyloidosis

Screening Carbon Nano Materials for Preventing Amyloid Protein Aggregation by Adopting a Facile Method

Development of a Highly Potent Transthyretin Amyloidogenesis Inhibitor: Design, Synthesis, and Evaluation

Inhibitors of Transthyretin Amyloidosis: How to Rank Drug Candidates Using X-ray Crystallography Data

Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis

Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition

Fabrication of an Antibody-Aptamer Sandwich Assay for Electrochemical Evaluation of Levels of Β-Amyloid Oligomers

Precise diagnosis and typing of early-stage renal immunoglobulin-derived amyloidosis by label-free quantification of parallel reaction monitoring-based targeted proteomics

Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations

Advances in targeted tracking and detection of soluble amyloid-β aggregates as a biomarker of Alzheimer's disease

Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease

Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis